Abstract: bronchial asthma is the most common disease among all pathologies of the respiratory system (more than 50%). In the world of AD, an average of 8% of adults and up to 10% of children suffer, with only 10-12% of all examined being diagnosed. According to the international classification system Anatomical Therapentical Chemical Classification, drugs used to treat asthma mainly belong to the groups R03 – drugs used for obstructive diseases of the respiratory tract.
In the Russian Federation, the availability of drugs is a priority area of the National Drug Policy that meets global trends. Accessibility is a comprehensive indicator that shows the availability of drugs depending on the index of price growth index, minimum wage and consumer basket. It has been established that 210 trade names of drugs used for the treatment of AD with all forms of release are registered in Russia. To determine the dynamics of wholesale prices for drugs, price growth indices were calculated: for 2012/2013 it amounted to 0.46%, respectively, for 2014/2013 – 0.73%, for 2015/2014 – 13.32%, for 2016/2015 – 31.23%.
A survey of pulmonologists and allergists made it possible to determine the actual attitude of specialists to the studied group of drugs of domestic and foreign manufacturers that are registered in the Russian Federation. The expert survey and the calculated multidimensional average in terms of parameters: effectiveness, frequency of prescriptions, prospects, availability in pharmacies, safety, it was revealed that the combined preparations have the highest ratings: combined preparations Berodual N, Seretid Diskus and Symbicort Turbuhaler, as well as Salbutamol-MHFP.
Keywords: bronchial asthma, treatment of asthma, expert estimations